The user experienced significant hair regrowth over four months using oral finasteride, oral minoxidil, micro-needling, and rosemary oil. They reported no side effects and emphasized the importance of continuing the treatment to maintain results.
PP405 might make minoxidil unnecessary, but finasteride or other 5AR inhibitors may still be needed. PP405 is expected to be expensive and not available until at least 2028, with limited information on its effectiveness.
Topical finasteride combined with minoxidil is used for hair loss treatment, with some users experiencing fewer side effects compared to oral finasteride. Morr-F, a topical solution, shows better results than minoxidil alone, with minimal adverse effects reported.
Creatine may cause hair loss in some individuals, especially those on finasteride, despite no scientific link. Personal experiences suggest individual sensitivity to DHT could be a factor.
A new hair loss treatment, pp405, may regrow hair better than finasteride and minoxidil, with potential availability by 2028. However, there is skepticism about its effectiveness and commercialization timeline.